EVGN - エボジェン (Evogene Ltd.) エボジェン

 EVGNのチャート


 EVGNの企業情報

symbol EVGN
会社名 Evogene Ltd (エボジェン)
分野(sector) Basic Industries   素材
産業(industry) Agricultural Chemicals  
業種    原材料・素材(Materials)
概要 事業概要 --   エボジェンはイスラエルの植物ゲノム会社。バイオテクノロジ―と高度育種法を駆使し、種子の成長と生産性の向上を促す包括的なソリュ―ションを影響。トウモロコシ、大豆、小麦、米等の主要作物の生産性の向上、および耐乾性と耐病性強化などの形質を付与する育種技術の開発に向けて、農業従事者と戦略的に業務提携を行う。   Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.
本社所在地 13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 165人
url www.evogene.com
nasdaq_url https://www.nasdaq.com/symbol/evgn
adr_tso
EBITDA EBITDA ー
終値(lastsale) 2.95
時価総額(marketcap) 75975176.15
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 EVGNのテクニカル分析


 EVGNのニュース

   Evogene''s unit Canonic ships cannabis varieties to Portugal  2022/01/31 14:47:38 Seeking Alpha
Evogene''s <> unit Canonic said it shipped the first batch of its unique cannabis varieties to Portugal, after receiving export approval by the Israeli Ministry of Health and
   Biomica/Bristol Myers on go with Phase I study of BMC-128 + Opdivo in cancer  2022/01/11 13:18:04 Seeking Alpha
Biomica and a subsidiary of Evogene (EVGN) announce that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept ((POC)), Phase I clinical trial
   Evogene Ltd Shares Close in on 52-Week Low - Market Mover  2022/01/09 03:40:26 Kwhen Finance
Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.58, giving the company a market cap of $66M. The stock is currently down 1.8% year-to-date, down 68.7% over the past 12 months, and down 68.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 10.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -75.0% The company's stock price performance over the past 12 months lags the peer average by 110.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Evogene Ltd Shares Near 52-Week Low - Market Mover  2021/12/29 12:58:57 Kwhen Finance
Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.60, giving the company a market cap of $67M. The stock is currently down 65.3% year-to-date, down 71.0% over the past 12 months, and down 68.0% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 56.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 395.8% The company's stock price performance over the past 12 months lags the peer average by 396.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Evogene Ltd. (NASDAQ:EVGN) Shares Acquired by Geode Capital Management LLC  2021/12/03 09:14:42 ETF Daily News
Geode Capital Management LLC grew its stake in Evogene Ltd. (NASDAQ:EVGN) by 40.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,731 shares of the biotechnology companys stock after purchasing an additional 7,761 shares during the period. Geode Capital Management LLC [] The post Evogene Ltd. (NASDAQ:EVGN) Shares Acquired by Geode Capital Management LLC appeared first on ETF Daily News .
   Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program  2021/11/30 12:00:00 PR Newswire
REHOVOT, Israel, Nov. 30, 2021 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program. In
   Evogene (NASDAQ:EVGN) Downgraded by Zacks Investment Research to Sell  2021/11/26 08:42:41 Transcript Daily
Zacks Investment Research lowered shares of Evogene (NASDAQ:EVGN) from a hold rating to a sell rating in a research note released on Monday, Zacks.com reports. According to Zacks, Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding []
   Evogene (NASDAQ:EVGN) Price Target Cut to $7.00  2021/11/25 10:14:42 Dakota Financial News
Evogene (NASDAQ:EVGN) had its price objective trimmed by Royal Bank of Canada from $8.00 to $7.00 in a research report report published on Wednesday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology companys stock. EVGN has been the subject of a number of other research reports. Roth Capital []
   LPL Financial LLC Boosts Position in Evogene Ltd. (NASDAQ:EVGN)  2021/11/22 09:10:43 Dakota Financial News
LPL Financial LLC lifted its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 21.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,485 shares of the biotechnology companys stock after purchasing an additional 10,625 shares during the quarter. LPL Financial LLC []
   Evogene (NASDAQ:EVGN) Announces Quarterly Earnings Results  2021/11/18 16:18:43 Dakota Financial News
Evogene (NASDAQ:EVGN) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by ($0.02), MarketWatch Earnings reports. Evogene had a negative net margin of 2,326.70% and a negative return on equity of 38.88%. During the same quarter in the prior year, []
   AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate  2021/07/06 11:30:00 PR Newswire
REHOVOT, Israel, July 6, 2021 /PRNewswire/ -- AgPlenus Ltd., a company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has achieved positive
   Agricultural Biotechnology Report 2021: Global Methodology, Research Findings, Size And Forecast To 2025| Evogene Ltd., Monsanto Company, Performance Plants Inc., KWS SAAT SE  2021/07/01 18:37:40 OpenPR
The report on the Global Agricultural Biotechnology Market includes basic research along with a comprehensive study of subjective and quantitative perspectives by various industry experts, leading home pioneers to gain an in-depth understanding of the market and industry practices. Based
   Evogene Announces Ms. Sarit Firon to become Evogene''s Chairperson of the Board  2021/06/23 11:00:00 PR Newswire
REHOVOT, Israel, June 23, 2021 /PRNewswire/ --Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that its Board of Directors has resolved to appoint Ms.
   Evogene: Bullish With Canonic''s Entry Into Israeli Medical Cannabis Markets  2021/06/16 07:26:22 Seeking Alpha
   Evogene Ltd. (EVGN) CEO Ofer Haviv on Q1 2021 Results - Earnings Call Transcript  2021/05/26 18:32:07 Seeking Alpha

 関連キーワード  (― 米国株 エボジェン EVGN Evogene Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)